Hong Kong Stock Movement: INNOGEN-B rises 18.69%, with clear capital flow, market sentiment triggers volatility attention

Hong Kong Stock Movement INNOGEN-B rose 18.69%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry PAG Biopharma-B rose 0.91%, with a trading volume of HKD 839 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Innovent Biologics fell 0.56%. Based on recent key news: On May 18, Innovent Biologics announced the latest R&D progress, focusing on top drug production for tumors, cardiovascular, and metabolic diseases. This news attracted market attention, leading to stock price fluctuations. Source: PR Newswire On May 19, the company issued a statement emphasizing that future business changes may lead to actual results differing from expectations. Such forward-looking statements increased market uncertainty, affecting the stock price. Source: Innovent Biologics On May 19, Innovent Biologics' business developments in San Francisco and Suzhou attracted investor attention, further impacting the stock price. Source: Innovent Biologics. The biopharmaceutical industry has recently experienced significant fluctuations and requires attention. Kangfang Biologics fell 1.49%, with a trading volume of HKD 520 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Market Capitalization in the Industry BeiGene fell 0.91%. Based on recent key news: On May 14, BeiGene announced that its drug, Tislelizumab, received FDA accelerated approval for the treatment of relapsed or refractory mantle cell lymphoma. This approval marks the first new BCL2 inhibitor approved in the U.S. in a decade, driving fluctuations in BeiGene's stock price. On May 11, Citigroup released a research report, raising BeiGene's U.S. stock target price to $453, emphasizing its strong Q1 performance with total revenue exceeding expectations, further boosting market confidence. On May 18, BeiGene's innovative layout in the solid tumor field received widespread attention, providing a new growth curve for early pipelines such as Tislelizumab, and despite fierce competition, the company's product portfolio in multiple areas has enhanced its risk resistance. The global pharmaceutical industry faces increasing pressure from patent cliffs